top of page
Response Pharmaceuticals’ Drug Candidate for the Treatment of Antipsychotic-Induced Weight Gain (AIWG) Achieves Primary Endpoint in Phase 1b Clinical Trial
April 23, 2024
Data show RDX-002 lowered postprandial triglycerides by 82%
Exploratory analyses also confirmed significantly reduced weight gain in subjects treated with olanzapine.
August 17, 2023
Response Pharmaceuticals Announces Successful Completion of Phase 1B Clinical Trial for RDX-002, a Novel Small Molecule for the Treatment of Antipsychotic-Induced Weight Gain
November 21, 2022
Response Pharmaceuticals Closes $8 Million Series A Financing to Fund Clinical Trials for Patients Suffering from Antipsychotic Induced Weight Gain
bottom of page